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buckling surgery. Visually acuity was maintained at 20/30 and 
retina was attached at 6‑month follow‑up.
CRM is rare congenital anomaly and consists of aberrant 
branch of a retinal vessel crossing the macula and horizontal 
raphe.[1] Commonly, CRM is a vein, but it may arise from an 
artery as well and is uusually asymptomatic.[1] Visual loss in 
patients with CRM has been attributed to serous detachment,[2] 
macro aneurysm,[3] branch retinal artery occlusion,[4] macular 
haemorrhage, vitreous haemorrhage,[5] foveal cyst, or mere 
presence of blood vessel.[1] FFA in CRM usually reveals early 
filling and delayed emptying and may be associated with 
dilated capillary bed surrounding the vessels.[6] CRM has never 
been reported in patient with RRD. The association of the two 
appears to be coincidental though.
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Figure 1: Colour fundus photograph (a) showing inferior rhegmatogenous 
retinal detachment with demarcation line. A branch of the infero‑temporal 
vein passes through the fovea. Fluorescein angiogram (b) shows 
demarcation line and confirms venous origin of congenital retinal 
macrovessel. Vertical spectral domain optical coherence tomography 






retinal toxicity in systemic lupus 
erythematosus
A 40‑year‑old African American female (AAF) with history 
of systemic lupus erythematosus on hydroxychloroquine 
200 mg twice daily (BID) for 10 years reported blurry vision 
for several months. Visual acuity was 20/30 in each eye. Color 
fundus photos [Fig. 1a and b] depict advanced bull’s eye 
maculopathy with marked retinal pigment epithelium and 
photoreceptor loss highlighted by autofluorescence imaging 
[Fig. 1c and d].  Spectral domain optical coherence tomography 
(SD‑OCT) imaging [Fig. 1e and f] demonstrates atrophic 
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screening after 5 years , minimally with OCT and automated 
visual field testing. Maximum daily hydroxychloroquine dose 
of 5mg/kg should be based on real body weight rather than 
ideal body weight.
Financial support and sponsorship
Nil.
Conflicts of interest
There are no conflicts of interest.
Kisha D Piggott, Rajendra Apte
Department of Ophthalmolgy and Visual Sciences, Washington 
University School of Medicine, St. Louis, MO 63110, USA
Correspondence to: Dr. Rajendra Apte, 
Department of Ophthalmolgy and Visual Sciences, 
Washington University School of Medicine, 660 S. Euclid Avenue, 
Box 8096, St. Louis, MO 63110, USA. 
E‑mail: apte@wustl.edu
Cite this article as: Piggott KD, Apte R. Hydroxychloroquine-induced retinal 
toxicity in systemic lupus erythematosus. Indian J Ophthalmol 2018;66:1861-2.
This is an open access journal, and articles are distributed under the terms of 
the Creative Commons Attribution‑NonCommercial‑ShareAlike 4.0 License, 
which allows others to remix, tweak, and build upon the work non‑commercially, 
as long as appropriate credit is given and the new creations are licensed under 
the identical terms.
Access this article online






Figure 1: Bilateral eye findings in 40 year old woman with systemic 
lupus erythematosus on hydroxychloroquine for 10 years. Fundus 
photos (a and b) depict advanced bull’s eye maculopathy in both 
eyes (arrow). Significantly decreased autofluorescence centrally with 
surrounding hyperfluorescence highlights marked retinal pigment 
epithelium and photoreceptor loss (c and d). Spectral domain optical 
coherence tomography imaging (e and f) demonstrates significant 
parafoveal outer retinal segment loss (arrow) and consequent “flying 






maculopathy bilaterally with significant outer retinal segment 
loss. Although retinal toxicity from hydroxychloroquine is 
rare, vision loss due to maculopathy is often irreversible and 
can be progressive. Despite the patient’s daily dose of the 
recommended <5 mg/kg, her use of the medication for 10 years, 
coupled with a cumulative dose of 1460 g, increased her risk 
for hydroxychloroquine‑related toxicity. Recommendation 
for immediate cessation of the hydroxychloroquine was 
communicated to the patient’s rheumatologist. American 
Academy of Ophthalmology recommends baseline and annual 
Combined central retinal vein 
occlusion and branch retinal artery 
occlusion
A 66‑years‑old female was diagnosed to have combined 
central retinal vein occlusion (CRVO) and branch retinal 
artery occlusion (BRAO). Colour fundus photograph [Fig. 1a] 
showing multiple haemorrhages and pale ischaemic area 
superiorly (black arrow). In Fig. 1b,   fundus fluorescein 
angiography (FFA) shows delayed arterial filling and 
prolonged arteriovenous transit time. Multicolour imaging 
highlights the area of ischaemia (black arrow) and serous fluid 
in macular area as dark green as shown in Fig. 1c. In Fig. 1d 
and e, optical coherence tomography shows hyper‑reflectivity 
of inner retinal layers (red arrow) and serous detachment 
(star), respectively.
Combined CRVO and BRAO is uncommon and the arterial 
occlusion is often missed.[1,2] Echocardiography, carotid Doppler 
ultrasound, and magnetic resonance imaging brain should be 
added whenever investigating a combined occlusion.[3]
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